Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the efficacy, safety, and survival benefit of
etoposide plus cisplatin and irinotecan plus cisplatin in first-line therapy of non-primary
pancreatic metastatic and/or unresectable gastrointestinal neuroendocrine tumor G3 type. In
addition, the investigators will explore the resistance mechanisms of gastrointestinal
neuroendocrine tumor G3, and screen out biomarkers that can predict the efficacy of
chemotherapy.